OBJECTIVE: The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers. METHODS: Western analysis and immune complex kinase assays were performed on a panel of human ovarian cancer cell lines and normal ovarian epithelial cell cultures, and immunohistochemical analysis for Src and activated Src were performed on a panel of late-stage human ovarian tumors. RESULTS AND CONCLUSIONS: Src is overexpressed and activated in a majority of late-stage ovarian tumors as well as in a panel of cultured malignant human ovarian epithelium grown in vitro, but not in normal ovarian epithelium (NOE) or immortalized NOE. Src overexpression was found to be frequently, but not always, associated with HER-2/neu overexpression, but no statistical association between Src and Her-2/neu overexpression could be demonstrated.
OBJECTIVE: The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers. METHODS: Western analysis and immune complex kinase assays were performed on a panel of humanovarian cancer cell lines and normal ovarian epithelial cell cultures, and immunohistochemical analysis for Src and activated Src were performed on a panel of late-stage humanovarian tumors. RESULTS AND CONCLUSIONS:Src is overexpressed and activated in a majority of late-stage ovarian tumors as well as in a panel of cultured malignant human ovarian epithelium grown in vitro, but not in normal ovarian epithelium (NOE) or immortalized NOE. Src overexpression was found to be frequently, but not always, associated with HER-2/neu overexpression, but no statistical association between Src and Her-2/neu overexpression could be demonstrated.
Authors: M J Choi; K H Cho; S Lee; Y J Bae; K J Jeong; S Y Rha; E J Choi; J H Park; J M Kim; J-S Lee; G B Mills; H Y Lee Journal: Oncogene Date: 2014-08-25 Impact factor: 9.867
Authors: John H Strickler; Shannon McCall; Andrew B Nixon; John C Brady; Herbert Pang; Christel Rushing; Allen Cohn; Alexander Starodub; Christy Arrowood; Sherri Haley; Kellen L Meadows; Michael A Morse; Hope E Uronis; Gerard C Blobe; S David Hsu; S Yousuf Zafar; Herbert I Hurwitz Journal: Invest New Drugs Date: 2013-11-01 Impact factor: 3.850
Authors: Angeles Alvarez Secord; Deanna Teoh; Jingquan Jia; Andrew B Nixon; Lisa Grace; David J Adams; Susan K Murphy Journal: Int J Gynecol Cancer Date: 2014-02 Impact factor: 3.437
Authors: Ayca Gucalp; Joseph A Sparano; James Caravelli; Jean Santamauro; Sujata Patil; Alyson Abbruzzi; Christine Pellegrino; Jackie Bromberg; Chau Dang; Maria Theodoulou; Joan Massague; Larry Norton; Clifford Hudis; Tiffany A Traina Journal: Clin Breast Cancer Date: 2011-05-03 Impact factor: 3.225
Authors: Cynthia S Collins; Jiyong Hong; Lisa Sapinoso; Yingyao Zhou; Zheng Liu; Kenneth Micklash; Peter G Schultz; Garret M Hampton Journal: Proc Natl Acad Sci U S A Date: 2006-02-28 Impact factor: 11.205
Authors: G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon Journal: Br J Cancer Date: 2009-10-27 Impact factor: 7.640